2026mag
ALNY May 2026 · Strong Buy
Alnylam is the pioneer in RNAi therapeutics, actively inflecting into sustained GAAP profitability. With a $665.75 base case fair value (+128% upside), the risk-reward is heavily skewed positive as the pipeline expands from rare to prevalent indications, validating its hyper-growth compounder archetype.Latest published research · analyzed 2026-05-13 · historical · sources unverified